Results 241 to 250 of about 3,890,842 (309)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Perinatal mental health research: priorities from a neurodiverse sample in the United Kingdom. [PDF]

Arch Womens Ment Health
Lautarescu A, Heraty S, Johnson C, Ruigrok A, Eaton E, Bazelmans T, Sigurdardottir J, Ratti V, Stone H, Anderson J, Javed A, Mahtani S, Lau-Zhu A, Smith DM.   +13 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Exploring Influencing Factors Including CYP2C19 Genotypes, and Developing a Machine Learning-Based Predictive Model for Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. [PDF]

Int J Gen Med
Xu B, Gu L, Lin G, Ni H, Shi H, Chen B.
europepmc   +1 more source

Platelet-Rich Plasma Accelerates the Return to Sport in Athletes with Acute Muscle Injuries: A Systematic Review and Statistical Fragility Index-Based Meta-Analysis of Randomized Controlled Trials. [PDF]

Sports Med Open
Bensa A, Fattini Fellini G, Boffa A, Grassi A, Samuelsson K, Filardo G.   +5 more
europepmc   +1 more source

Patient-Led Peer Support Groups Improve Anti-Hypertensive Drugs Access for Adults Living with HIV and Hypertension in Rural Uganda - A Cross-Sectional Study. [PDF]

HIV AIDS (Auckl)
Atukunda M, Twinamatsiko B, Ayebare M, Arinitwe E, Kawuma AN, Kiguba R, Nangendo J, Mutungi G, Semitala FC, Kamya MR, Kabami J.   +10 more
europepmc   +1 more source

The co-occurrence of ingroup and outgroup prosociality requires cross-group partner choice. [PDF]

Proc Natl Acad Sci U S A
Xiao Q, Imada H.
europepmc   +1 more source